Literature DB >> 24468896

Risk factors for clinical events at 1-year follow-up after drug-eluting stent implantation: results from the prospective multicenter German DES.DE registry.

I Akin1, C A Nienaber, G Richardt, R Tölg, M Hochadel, S Schneider, J Senges, U Tebbe, U Zeymer, G Sabin, K-H Kuck, M W Bergmann.   

Abstract

BACKGROUND: Drug-eluting stents (DES) have substantially reduced target vessel revascularization (TVR) after percutaneous coronary interventions. Risk factors for clinical events need to be redefined with this treatment option. METHODS AND
RESULTS: In the prospective DES.DE registry, baseline clinical and angiographic characteristics as well as in-hospital and follow-up events were recorded for all enrolled patients. Between October 2005 and May 2009, 21,774 patients receiving DES were enrolled at 98 DES.DE sites. The composite of death, myocardial infarction (MI) and stroke defined as major adverse cardiac and cerebrovascular events (MACCE) and TVR were predefined as primary endpoints. At 1-year follow-up rates for overall death, MI, stroke, MACCE, TVR and definite stent thrombosis were 2.7, 3.1, 1.4, 7.1, 11.5 and 0.6 %, respectively. Aside from well-known risk factors like age, diabetes mellitus and triple-vessel disease, stratification in patients with or without MACCE revealed atrial fibrillation, non-ST-segment elevation myocardial infarction, renal failure, impaired ejection fraction and peripheral vascular disease as strong predictors of MACCE at 1 year.
CONCLUSION: Data collected in the DES.DE registry, reflecting the clinical practice in Germany, revealed favorable clinical outcomes after DES implantation in a real world setting but also identifying several high-risk populations.

Entities:  

Mesh:

Year:  2014        PMID: 24468896     DOI: 10.1007/s00392-014-0662-x

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  26 in total

1.  ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention).

Authors:  Sidney C Smith; Ted E Feldman; John W Hirshfeld; Alice K Jacobs; Morton J Kern; Spencer B King; Douglass A Morrison; William W O'Neil; Hartzell V Schaff; Patrick L Whitlow; David O Williams; Elliott M Antman; Cynthia D Adams; Jeffrey L Anderson; David P Faxon; Valentin Fuster; Jonathan L Halperin; Loren F Hiratzka; Sharon Ann Hunt; Rick Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel
Journal:  Circulation       Date:  2006-02-21       Impact factor: 29.690

2.  Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies.

Authors:  Ajay J Kirtane; Anuj Gupta; Srinivas Iyengar; Jeffrey W Moses; Martin B Leon; Robert Applegate; Bruce Brodie; Edward Hannan; Kishore Harjai; Lisette Okkels Jensen; Seung-Jung Park; Raphael Perry; Michael Racz; Francesco Saia; Jack V Tu; Ron Waksman; Alexandra J Lansky; Roxana Mehran; Gregg W Stone
Journal:  Circulation       Date:  2009-06-15       Impact factor: 29.690

3.  Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry).

Authors:  Christoph A Nienaber; Ibrahim Akin; Steffen Schneider; Jochen Senges; Thomas Fetsch; Ulrich Tebbe; Stefan N Willich; Jürgen Stumpf; Georg V Sabin; Sigmund Silber; Gert Richardt; Karl-Heinz Kuck
Journal:  Am J Cardiol       Date:  2009-09-26       Impact factor: 2.778

4.  Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease.

Authors:  Gregg W Stone; Ali Rizvi; William Newman; Kourosh Mastali; John C Wang; Ronald Caputo; Julie Doostzadeh; Sherry Cao; Charles A Simonton; Krishnankutty Sudhir; Alexandra J Lansky; Donald E Cutlip; Dean J Kereiakes
Journal:  N Engl J Med       Date:  2010-05-06       Impact factor: 91.245

5.  Comparison between on-label versus off-label use of drug-eluting coronary stents in clinical practice: results from the German DES.DE-Registry.

Authors:  Timm Bauer; Christoph A Nienaber; Ibrahim Akin; Karl-Heinz Kuck; Matthias Hochadel; Jochen Senges; Thomas Fetsch; Ulrich Tebbe; Stefan N Willich; Jürgen Stumpf; Georg V Sabin; Sigmund Silber; Gert Richardt; Ralf Zahn
Journal:  Clin Res Cardiol       Date:  2011-03-18       Impact factor: 5.460

6.  Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial.

Authors:  Sigmund Silber; Stephan Windecker; Pascal Vranckx; Patrick W Serruys
Journal:  Lancet       Date:  2011-04-01       Impact factor: 79.321

7.  Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System).

Authors:  Dean J Kereiakes; Donald E Cutlip; Robert J Applegate; John Wang; Manejeh Yaqub; Poornima Sood; Xiaolu Su; Guoping Su; Naim Farhat; Ali Rizvi; Charles A Simonton; Krishnankutty Sudhir; Gregg W Stone
Journal:  J Am Coll Cardiol       Date:  2010-12-14       Impact factor: 24.094

8.  Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease.

Authors:  Patrick W Serruys; Marie-Claude Morice; A Pieter Kappetein; Antonio Colombo; David R Holmes; Michael J Mack; Elisabeth Ståhle; Ted E Feldman; Marcel van den Brand; Eric J Bass; Nic Van Dyck; Katrin Leadley; Keith D Dawkins; Friedrich W Mohr
Journal:  N Engl J Med       Date:  2009-02-18       Impact factor: 91.245

Review 9.  Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis.

Authors:  Christoph Stettler; Simon Wandel; Sabin Allemann; Adnan Kastrati; Marie Claude Morice; Albert Schömig; Matthias E Pfisterer; Gregg W Stone; Martin B Leon; José Suarez de Lezo; Jean-Jacques Goy; Seung-Jung Park; Manel Sabaté; Maarten J Suttorp; Henning Kelbaek; Christian Spaulding; Maurizio Menichelli; Paul Vermeersch; Maurits T Dirksen; Pavel Cervinka; Anna Sonia Petronio; Alain J Nordmann; Peter Diem; Bernhard Meier; Marcel Zwahlen; Stephan Reichenbach; Sven Trelle; Stephan Windecker; Peter Jüni
Journal:  Lancet       Date:  2007-09-15       Impact factor: 79.321

10.  Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology.

Authors:  Sigmund Silber; Per Albertsson; Francisco F Avilés; Paolo G Camici; Antonio Colombo; Christian Hamm; Erik Jørgensen; Jean Marco; Jan-Erik Nordrehaug; Witold Ruzyllo; Philip Urban; Gregg W Stone; William Wijns
Journal:  Eur Heart J       Date:  2005-03-15       Impact factor: 29.983

View more
  7 in total

1.  Clinical outcome after percutaneous treatment of de novo coronary bifurcation lesions using first or second generation of drug-eluting stents.

Authors:  Miroslaw Ferenc; Heinz Joachim Buettner; Michael Gick; Thomas Comberg; Juergen Rothe; Firas Khoury; Christian Valina; Aurel Toma; Piotr Kuebler; Florian Riede; Franz-Josef Neumann
Journal:  Clin Res Cardiol       Date:  2015-09-02       Impact factor: 5.460

2.  Correlation between optical coherence tomography-derived intraluminal parameters and fractional flow reserve measurements in intermediate grade coronary lesions: a comparison between diabetic and non-diabetic patients.

Authors:  Sebastian Reith; Simone Battermann; Martin Hellmich; Nikolaus Marx; Mathias Burgmaier
Journal:  Clin Res Cardiol       Date:  2014-08-15       Impact factor: 5.460

3.  Deterioration of renal function at stent implantation can predict long-term outcome after stent thrombosis.

Authors:  Vojko Kanic; Meta Penko; Franjo Husam Naji; Robert Ekart; Zlatka Kanic; Dejan Dinevski; Radovan Hojs
Journal:  Wien Klin Wochenschr       Date:  2015-09-16       Impact factor: 1.704

4.  External validity of the "all-comers" design: insights from the BIOSCIENCE trial.

Authors:  Anna Franzone; Dik Heg; Lorenz Räber; Marco Valgimigli; Raffaele Piccolo; Thomas Zanchin; Kyohei Yamaji; Stefan Stortecky; Stefan Blöchlinger; Lukas Hunziker; Fabien Praz; Peter Jüni; Stephan Windecker; Thomas Pilgrim
Journal:  Clin Res Cardiol       Date:  2016-04-01       Impact factor: 5.460

Review 5.  Cardiac implant registries 2006-2016: a systematic review and summary of global experiences.

Authors:  Shixuan Zhang; Sebastian Gaiser; Peter L Kolominsky-Rabas
Journal:  BMJ Open       Date:  2018-04-12       Impact factor: 2.692

6.  Drug-eluting stents in clinical routine: a 1-year follow-up analysis based on German health insurance administrative data from 2008 to 2014.

Authors:  Elke Jeschke; Julia Searle; Christian Günster; Henning Thomas Baberg; Peter Dirschedl; Benny Levenson; Jürgen Malzahn; Thomas Mansky; Martin Möckel
Journal:  BMJ Open       Date:  2017-07-28       Impact factor: 2.692

7.  Bifurcation treatment with novel, highly flexible drug-eluting coronary stents in all-comers: 2-year outcome in patients of the DUTCH PEERS trial.

Authors:  Liefke C van der Heijden; Marlies M Kok; Ming Kai Lam; Peter W Danse; Alexander R Schramm; Gillian A J Jessurun; R Melvyn Tjon Joe Gin; K Gert van Houwelingen; Raymond W M Hautvast; Gerard C M Linssen; Hanim Sen; Marije M Löwik; Maarten J IJzerman; Carine J M Doggen; Clemens von Birgelen
Journal:  Clin Res Cardiol       Date:  2015-09-02       Impact factor: 5.460

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.